ATE141514T1 - Verfahren zur verhütung, stabilisierung oder verursachung des zurückgangs von atherosklerose durch anwendung einer mischung von einem cholesterol-vermindernden arzneimittel mit einem ace-inhibitor - Google Patents

Verfahren zur verhütung, stabilisierung oder verursachung des zurückgangs von atherosklerose durch anwendung einer mischung von einem cholesterol-vermindernden arzneimittel mit einem ace-inhibitor

Info

Publication number: ATE141514T1
Authority: AT; Austria
Prior art keywords: atherosclerosis; cholesterol; ace inhibitor; stabilizing; preventing
Prior art date: 1990-05-15

Application number

AT91304232T

Other languages

English (en)

Inventor

James L Bergey

James C Kawano

Werner Tschollar

Cary S Yonce

Original Assignee

Squibb & Sons Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-05-15

Filing date

1991-05-10

Publication date

1996-09-15

1991-05-10 Application filed by Squibb & Sons Inc filed Critical Squibb & Sons Inc

1996-09-15 Application granted granted Critical

1996-09-15 Publication of ATE141514T1 publication Critical patent/ATE141514T1/de

Links

239000005541 ACE inhibitor Substances 0.000 title abstract 2
201000001320 Atherosclerosis Diseases 0.000 title abstract 2
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 title abstract 2
239000003529 anticholesteremic agent Substances 0.000 title abstract 2
239000000203 mixture Substances 0.000 title 1
230000000087 stabilizing effect Effects 0.000 title 1
206010020772 Hypertension Diseases 0.000 abstract 1
TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 abstract 1
230000003143 atherosclerotic effect Effects 0.000 abstract 1
229960000830 captopril Drugs 0.000 abstract 1
FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 abstract 1
230000001631 hypertensive effect Effects 0.000 abstract 1
230000003902 lesion Effects 0.000 abstract 1
TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 abstract 1
229960002965 pravastatin Drugs 0.000 abstract 1
125000003396 thiol group Chemical group [H]S* 0.000 abstract 1
229960002769 zofenopril Drugs 0.000 abstract 1
IAIDUHCBNLFXEF-MNEFBYGVSA-N zofenopril Chemical compound C([C@@H](C)C(=O)N1[C@@H](C[C@@H](C1)SC=1C=CC=CC=1)C(O)=O)SC(=O)C1=CC=CC=C1 IAIDUHCBNLFXEF-MNEFBYGVSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Heart & Thoracic Surgery (AREA)
Obesity (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Diabetes (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AT91304232T 1990-05-15 1991-05-10 Verfahren zur verhütung, stabilisierung oder verursachung des zurückgangs von atherosklerose durch anwendung einer mischung von einem cholesterol-vermindernden arzneimittel mit einem ace-inhibitor ATE141514T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US52426690A	1990-05-15	1990-05-15

Publications (1)

Publication Number	Publication Date
ATE141514T1 true ATE141514T1 (de)	1996-09-15

Family

ID=24088484

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT91304232T ATE141514T1 (de)	1990-05-15	1991-05-10	Verfahren zur verhütung, stabilisierung oder verursachung des zurückgangs von atherosklerose durch anwendung einer mischung von einem cholesterol-vermindernden arzneimittel mit einem ace-inhibitor

Country Status (15)

Country	Link
EP (1)	EP0457514B1 (de)
JP (1)	JPH04226921A (de)
KR (1)	KR100200467B1 (de)
AT (1)	ATE141514T1 (de)
AU (1)	AU651579B2 (de)
CA (1)	CA2040865C (de)
DE (1)	DE69121464T2 (de)
DK (1)	DK0457514T3 (de)
ES (1)	ES2090244T3 (de)
GR (1)	GR3021703T3 (de)
HU (1)	HU212102B (de)
IE (1)	IE77637B1 (de)
NZ (1)	NZ237929A (de)
PT (1)	PT97660B (de)
ZA (1)	ZA913509B (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5157025A (en) *	1991-04-01	1992-10-20	E. R. Squibb & Sons, Inc.	Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug
WO1993013801A1 (en) *	1992-01-17	1993-07-22	The Procter & Gamble Company	Treatment for atherosclerosis
WO1995013063A1 (en) *	1993-11-09	1995-05-18	Merck & Co., Inc.	HMG-CoA REDUCTASE INHIBITORS IN THE NORMALIZATION OF VASCULAR ENDOTHELIAL DYSFUNCTION
DE4402379C2 (de) *	1994-01-27	1997-09-25	Lohmann Therapie Syst Lts	Orale Arzneiform mit sauren Wirkstoffen und Verfahren zu ihrer Herstellung
WO1995026188A1 (en) *	1994-03-29	1995-10-05	Merck & Co., Inc.	Treatment of atherosclerosis with angiotensin ii receptor blocking imidazoles
EP2253327A1 (de) *	1996-04-05	2010-11-24	Takeda Pharmaceutical Company Limited	Pharmazeutische Zusammensetzung enthaltend eine Angiotensin-II antagonistisch wirkende Verbindung in Kombination mit einer anderen Verbindung
EP1514543A1 (de)	1997-08-29	2005-03-16	Pfizer Inc.	Kombinationstherapie, enthaltend Atorvastatin und blutdrucksenkendes Mittel
SI20305A (sl)	1999-08-06	2001-02-28	LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d.	Kristali natrijeve soli pravastatina
AU2007200367B2 (en) *	1999-02-06	2010-04-08	Astrazeneca Ab	Use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy
GB0001662D0 (en)	1999-02-06	2000-03-15	Zeneca Ltd	Pharmaceutical compositions
US6172441B1 (en)	1999-06-28	2001-01-09	Visteon Global Technologies, Inc.	Rotor assembly
BR0013704A (pt)	1999-08-30	2002-05-07	Aventis Pharma Gmbh	Uso de inibidores do sistema renina-angiotensina na prevenção de casos cardiovasculares
US6982251B2 (en)	2000-12-20	2006-01-03	Schering Corporation	Substituted 2-azetidinones useful as hypocholesterolemic agents
PT1355644E (pt)	2001-01-26	2006-11-30	Schering Corp	Utilização de compostos azetidinona substituídos para o tratamento de sitosterolemia
US7071181B2 (en)	2001-01-26	2006-07-04	Schering Corporation	Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
ES2274013T3 (es)	2001-01-26	2007-05-16	Schering Corporation	Combinaciones de activador(es) del receptor activado por el proliferador de los peroxisomas (ppar) e inhibidor(es)m de la absorcion de estelores y tratamientos para trastornos vasculares.
US6576256B2 (en)	2001-08-28	2003-06-10	The Brigham And Women's Hospital, Inc.	Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US6669955B2 (en) *	2001-08-28	2003-12-30	Longwood Pharmaceutical Research, Inc.	Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US7053080B2 (en)	2001-09-21	2006-05-30	Schering Corporation	Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7056906B2 (en)	2001-09-21	2006-06-06	Schering Corporation	Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
JP2005504091A (ja)	2001-09-21	2005-02-10	シェーリング　コーポレイション	ステロール吸収阻害剤としてアゼチジノンを用いる黄色腫の処置
US20040137054A1 (en) *	2002-05-03	2004-07-15	Alexandra Hager	Stable pharmaceutical formulation for a combination of a statin and an ace-inhibitors
AR040588A1 (es)	2002-07-26	2005-04-13	Schering Corp	Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
US7560449B2 (en)	2002-11-06	2009-07-14	Schering Corporation	Methods and therapeutic combinations for the treatment of demyelination
ES2311806T3 (es)	2003-03-07	2009-02-16	Schering Corporation	Compuesto de azetidinona sustituidos, fornulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
EP1606287B1 (de)	2003-03-07	2013-10-02	Merck Sharp & Dohme Corp.	Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
WO2004081003A1 (en)	2003-03-07	2004-09-23	Schering Corporation	Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholeterolemia
US7459442B2 (en)	2003-03-07	2008-12-02	Schering Corporation	Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
WO2004085448A2 (en) *	2003-03-19	2004-10-07	Genzyme Corporation	Unsaturated phosphinyl-phosphonate phosphate transport inhibitors
GB0322552D0 (en)	2003-09-26	2003-10-29	Astrazeneca Uk Ltd	Therapeutic treatment
JP2012510511A (ja) *	2008-12-01	2012-05-10	インヴアスクセラピューテイックスインコーポレイテッド	レニン−アンジオテンシン−アルドステロン系阻害剤及びリポ酸化合物を含有する組成物、並びに、レニン−アンジオテンシン−アルドステロン系に関連した疾患の治療のためのそれらの使用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3536687A1 (de) *	1985-10-15	1987-04-16	Hoechst Ag	Verfahren zur behandlung von atherosklerose, thrombose und der peripheren gefaesskrankheit

1991
- 1991-04-19 CA CA002040865A patent/CA2040865C/en not_active Expired - Lifetime
- 1991-04-24 NZ NZ237929A patent/NZ237929A/en unknown
- 1991-04-26 AU AU76270/91A patent/AU651579B2/en not_active Expired
- 1991-04-29 IE IE143191A patent/IE77637B1/en not_active IP Right Cessation
- 1991-05-08 ZA ZA913509A patent/ZA913509B/xx unknown
- 1991-05-10 AT AT91304232T patent/ATE141514T1/de not_active IP Right Cessation
- 1991-05-10 ES ES91304232T patent/ES2090244T3/es not_active Expired - Lifetime
- 1991-05-10 EP EP91304232A patent/EP0457514B1/de not_active Expired - Lifetime
- 1991-05-10 DE DE69121464T patent/DE69121464T2/de not_active Expired - Lifetime
- 1991-05-10 DK DK91304232.1T patent/DK0457514T3/da active
- 1991-05-14 PT PT97660A patent/PT97660B/pt not_active IP Right Cessation
- 1991-05-14 KR KR1019910007749A patent/KR100200467B1/ko not_active Expired - Lifetime
- 1991-05-14 HU HU911620A patent/HU212102B/hu unknown
- 1991-05-15 JP JP3110268A patent/JPH04226921A/ja not_active Withdrawn
1996
- 1996-11-19 GR GR960403096T patent/GR3021703T3/el unknown

Also Published As

Publication number	Publication date
DE69121464D1 (de)	1996-09-26
DK0457514T3 (da)	1996-09-16
HU911620D0 (en)	1991-11-28
EP0457514A1 (de)	1991-11-21
KR910019614A (ko)	1991-12-19
CA2040865C (en)	2002-07-23
IE77637B1 (en)	1997-12-31
CA2040865A1 (en)	1991-11-16
ES2090244T3 (es)	1996-10-16
EP0457514B1 (de)	1996-08-21
KR100200467B1 (ko)	1999-06-15
AU651579B2 (en)	1994-07-28
GR3021703T3 (en)	1997-02-28
PT97660B (pt)	1998-09-30
HU212102B (en)	1996-02-28
AU7627091A (en)	1991-11-21
PT97660A (pt)	1992-02-28
DE69121464T2 (de)	1997-03-27
ZA913509B (en)	1992-02-26
NZ237929A (en)	1997-06-24
IE911431A1 (en)	1991-11-20
JPH04226921A (ja)	1992-08-17
HUT57993A (en)	1992-01-28

Legal Events

Date	Code	Title	Description
1997-04-15	UEP	Publication of translation of european patent specification
2011-08-15	EELA	Cancelled due to lapse of time

Publication	Publication Date	Title
ATE141514T1 (de)	1996-09-15	Verfahren zur verhütung, stabilisierung oder verursachung des zurückgangs von atherosklerose durch anwendung einer mischung von einem cholesterol-vermindernden arzneimittel mit einem ace-inhibitor
DE69628874D1 (de)	2003-08-07	Verwendung eines HMG CoA-Reduktase Inhibitors zur Vorbeugung eines zweiten Herzanfalls
ATE161536T1 (de)	1998-01-15	Neue mercaptoacetylamid-derivate zur verwendung als enkephalinase- und ace-hemmer
ATE81979T1 (de)	1992-11-15	Pharmazeutische zusammensetzung und verfahren zur virushemmung.
DE59404719D1 (de)	1998-01-15	Verfahren zur Herstellung von Diarylcarbonaten
DE68918191D1 (de)	1994-10-20	Verfahren zur Lactonisierung von Mevinsäuren und deren Analogen.
DE69225128D1 (de)	1998-05-20	Verfahren zur Aufbereitung von sich berührendem und degradiertem Text
DE69428403D1 (de)	2001-10-31	Verfahren zur Herstellung von Azetidinverbindungen und Ausgangsverbindungen dafür
DE59402624D1 (de)	1997-06-12	Verfahren zur Herstellung von Cycloolefincopolymeren
DE59403432D1 (de)	1997-08-28	Verfahren zur Direktreduktion von Eisenoxide enthaltenden Stoffen
DE69324689D1 (de)	1999-06-02	Verwendung von diacylglycerolen zur steigerung des melaningehaltes in melanozyten
DE69409595D1 (de)	1998-05-20	Verfahren zur Herstellung von Dialkylcarbonat
DE59401215D1 (de)	1997-01-23	Verfahren zur Verhinderung des Reissens von Bambusrohren (mechanisch)
ATE142884T1 (de)	1996-10-15	Verwendung von magnesium-pyridoxal-5'-phosphat- glutaminat zur verhinderung von krankheiten verursacht durch gefässläsionen
MD960168A (ro)	1998-04-30	Metodă şi compuşi pentru tratamentul infecţiilor virale
FI961380A7 (fi)	1996-03-26	Koostumuksia virusten aiheuttamien kasvainten ehkäisemiseksi ja hoitam iseksi
DE59300921D1 (de)	1995-12-21	Verfahren zur Herstellung von beta-Hydroxycarbonsäureestern.
DE59402114D1 (de)	1997-04-24	Verfahren zur Herstellung von Dialkylcarbonaten
DE59404315D1 (de)	1997-11-20	Verfahren zur Herstellung von Dialkylcarbonaten
DE59408420D1 (de)	1999-07-22	Niedrigviskose kosmetische und pharmazeutische emulsionen
DE59402901D1 (de)	1997-07-03	Verfahren zur Herstellung von 5-Fluoranthranilsäurealkylestern und/oder 5-Fluoranthranilsäure
DE69116149D1 (de)	1996-02-15	Verfahren zur Herstellung von Acrylestern
DE59209484D1 (de)	1998-10-08	Verfahren zur reinigung von gebrauchten schmierölen
DE69131058D1 (de)	1999-05-06	Verwendung einer therapeutischen Zusammensetzung zur Behandlung von Bronchitis
DE69422953D1 (de)	2000-03-16	Verfahren zur Herstellung von D-Milchsäure und L-Lactamid